Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA issues proposed order requiring PMAs for automated external defibrillators. Allergan's Juvéderm Voluma XC dermal filler gets panel date. More regulatory news.
You may also be interested in...
News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.
Industry Fights FDA’s PMA Proposal For External Defibrillators
Makers of automated external defibrillators are vigorously opposed to FDA’s proposal to require PMAs for the devices. A petition submitted by Philips Healthcare asks the agency to reclassify the devices into class II with special controls.
CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices
Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.